louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06468150: Mechanical Thrombectomy and Catheter Directed Thrombolysis Utilization in Patients With Deep Vein Thrombosis
Official title: Mechanical Thrombectomy and Catheter Directed Thrombolysis Utilization in Patients With Deep Vein Thrombosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Deep Vein Thrombosis
Keywords: Mechanical thrombectomy
catheter directed thrombolysis
iliofemoral deep vein thrombosis
Lead sponsor: Pirogov Russian National Research Medical University
Sponsor class: OTHER
First posted: 2024-06-21
Enrollment: 2427
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with deep vein thrombosis referred to the hospital from January 2022 to December 2023.

Brief summary: The goal of this observational study is to assess the utilization of mechanical thrombectomy and catheter-directed thrombolysis in patients with deep vein thrombosis in tertiary care. The main questions it aims to answer are:

1. How many patients with deep vein thrombosis are potentially eligible for mechanical thrombectomy and catheter-directed thrombolysis in a tertiary hospital?
2. What is the actual number of patients undergoing endovascular interventions for deep vein thrombosis?

Participants received endovascular treatment according to the clinical protocol of the treatment.

Detailed description: Tertiary hospital database was analyzed. All the records of patients referred for deep vein thrombosis were extracted. The collected data included general patient information, medical history, results of physical examination, duplex ultrasound, laboratory analysis, etc. Indications and contraindications for mechanical thrombectomy and catheter-directed thrombolysis were assessed, considering possible benefits and risks. Patients who could be eligible for this technique were identified

Eligibility criteria: Inclusion Criteria:

* lower limb, pelvic, or inferior vena cava deep vein thrombosis

Exclusion Criteria:

-

Primary outcomes:
measure: Number of patients with deep vein thrombosis who could be eligible for mechanical thrombectomy and catheter-directed thrombolysis
timeFrame: from date of admission until the date of discharge, up to 1-2 weeks
Secondary outcomes:
measure: The number of patients with deep vein thrombosis who underwent mechanical thrombectomy and catheter-directed thrombolysis
timeFrame: from date of admission until the date of discharge, up to 1-2 weeks
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation
Study officials:
References:
Clinical trial NCT02780050: Influence of Core Muscles Activation Using Physical Fitness on the Performance of Chest Compression
Official title: Influence of Core Muscles Activation Using Physical Fitness on the Performance of Chest Compression
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Arrest
Keywords: cardiopulmonary resuscitation
manikins
physical fitness
Lead sponsor: Hallym University Kangnam Sacred Heart Hospital
Sponsor class: OTHER
First posted: 2016-05-23
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Chest compression, a key component of cardiopulmonary resuscitation (CPR), has a major role for survival of cardiac arrest patients. According to 2015 American heart association (AHA) guideline, rescuers provide high quality CPR to adult cardiac arrest patients including 5 to 6 cm depth and 100 to 120 beat per minute rate chest compression.

However, in CPR situation, chest compression depth and rate vary according to provider's muscle strength. In other words, the individual difference of the degree of physical activity will make the different result for CPR. So, the investigators hypothesize that the core muscles activation using physical fitness improves the quality of chest compression and the quality of CPR, eventually.


Eligibility criteria: Inclusion Criteria:

* medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education

Exclusion Criteria:

* patients with musculoskeletal disease
* patients with cardiovascular disease
* patients with lung disease

Primary outcomes:
measure: mean chest compression depth
timeFrame: 1 Day
Secondary outcomes:
measure: the ratio of complete chest compression (5 to 6cm depth, complete chest recoil) to all chest compression
timeFrame: 1 Day
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kangnam Sacred Heart Hospital
Study officials:
References:
Clinical trial NCT00332150: Mothers' Approach to Clinical Research Amongst Their Preterm or Healthy Newborns
Official title: Mothers' Approach to Clinical Research Amongst Their Preterm or Healthy Newborns
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parents Approval to Research
Keywords: parents
newborn
clinical trials
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2006-06-01
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE

Brief summary: Parental approval to enroll their sick children in clinical research was studied. However, the motivation of parents to enroll healthy children and/or babies was not yet studied. The importance of clinical research among the healthy population is of extreme value. The aim of this study is to assess the motivation, medical trust and other factors influencing parents' decision to enroll their healthy baby in a clinical study.

Detailed description: Mothers to either healthy full-term babies post delivery or preterms will be asked to anonymously answer a questionnaire. The questionnaire includes demographic data, questions regarding their approach to medical issues, factors that influence her to enroll her baby in a research trial (different research types, different benefits from the research and fears). Finally, the mother will be asked if she will be willing to enroll her baby to on-going studies in the department.

Eligibility criteria: Inclusion Criteria:

* Mothers to healthy newborns during hospital stay after delivery, and mothers of preterm infants during their hospitalization in NICU.

Exclusion Criteria:

* Mothers of sick newborns (respiratory distress, receiving IV infusion, etc.) who are in the special care for newborns.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ramat Gan
country: Israel
facility: Sheba Medical Center
Study officials:
affiliation: Sheba Medical Center
name: Ayala Maayan, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Zupancic JA, Gillie P, Streiner DL, Watts JL, Schmidt B. Determinants of parental authorization for involvement of newborn infants in clinical trials. Pediatrics. 1997 Jan;99(1):E6. doi: 10.1542/peds.99.1.e6.
citation: Maayan-Metzger A, Kedem-Friedrich P, Kuint J. Motivations of mothers to enroll their newborn infants in general clinical research on well-infant care and development. Pediatrics. 2008 Mar;121(3):e590-6. doi: 10.1542/peds.2007-1571.
Clinical trial NCT04853550: Long-Term Follow-up After Ventral Hernia Repair With Strattice Mesh
Official title: Long Term Follow-up After Ventral Hernia Repair With Strattice Mesh
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ventral Hernia
Lead sponsor: University of Louisville
Sponsor class: OTHER
Collaborators: name: AllerGen NCE Inc.
First posted: 2021-04-21
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects who have undergone ventral hernia repair with Strattice Mesh between January 1, 2013 and November 1, 2019

Brief summary: This study will assess long-term outcomes (greater than 12 months) following ventral hernia repair with Strattice mesh reinforcement.

Detailed description: Subjects will be retrospectively identified as having undergone operative repair of ventral hernia with Strattice mesh reinforcement during the period January 1, 2013 - November 1, 2017. Follow-up data will be collected either at a postoperative clinic visit or via telephone interview.

Eligibility criteria: Inclusion Criteria:

* Hernia repair with Strattice Mesh
* Age 18 or older

Exclusion Criteria:

* Under age 18
* No history of hernia repair

Primary outcomes:
measure: Hernia recurrence
timeFrame: 24 Months
Secondary outcomes:
measure: Quality of LIfe Questionnaire
timeFrame: 24 Months
Other outcomes:
Locations:
city: Louisville
country: United States
facility: University of Louisville
state: Kentucky
Study officials:
affiliation: University of Louisville
name: Farid Kehdy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00385450: Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor
Official title: Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor in the Perioperative Period
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Cardiopulmonary Bypass
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2006-10-09
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: In previous studies, 90% of patients who underwent elective cardiopulmonary bypass procedure manifested CD4 counts of less than 500 cells/microliter in the immediate (day 1) post-operative period. This study will investigate whether or not Nelfinavir increases those CD4 counts in the post-operative period.

Detailed description: See Brief Summary.

Eligibility criteria: Inclusion Criteria:

* Any patient undergoing elective (non-emergency) cardiopulmonary bypass for coronary artery bypass grafting, cardiac valve replacement, or both.

Exclusion Criteria:

* A dozen different medical conditions and two dozen medical contraindications.

Primary outcomes:
measure: Proportion of Nelfinavir patients v. proportion of placebo patients who have CD4 counts of less than 500 cells/microliter
timeFrame: Six days.
Secondary outcomes:
measure: Changes in quantitative measure of inflammatory markers
timeFrame: Six days.
measure: Changes in clinical outcomes.
timeFrame: Six days.
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Andrew D. Badley, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01062750: Liver Regeneration Therapy by Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells
Official title: Liver Regeneration Therapy by Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Liver Cirrhosis
Keywords: Liver Cirrhosis
Lead sponsor: Kanazawa University
Sponsor class: OTHER
First posted: 2010-02-04
Enrollment: 4
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Mesenchymal stem cells have capability to differentiate into hepatocyte and will be useful for liver regeneration. Adipose tissue is relatively enriched with mesenchymal stem cell compared to bone marrow tissue. In this trial, eligible liver cirrhosis patients will receive autologous adipose tissue derived stromal cells through intrahepatic arterial catheterization.

Detailed description: The population of the liver cirrhosis patients is enormous in Japan and the only radical treatment for them is liver transplantation: however, the number of giving donor is extremely limited. Mesenchymal stem cells have been capable to differentiate into mesodermal-lineage cells as well as endodermal-lineage cells such as hepatocytes. They reside in the mesenchymal tissues such as bone marrows as well as adipose tissues. The latter tissues are relatively enriched with mesenchymal stem cells compared to bone marrow cells. In this study, the cirrhotic patients will undergo intrahepatic arterial administration of autologous adipose tissue derived stromal cells through catheter.

Eligibility criteria: Criteria defined in the implementation protocol

Primary outcomes:
measure: all cause harmful events
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Kanazawa
country: Japan
facility: Kanazawa University Hospital
state: Ishikawa
Study officials:
affiliation: Kanazawa University
name: Shuichi Kaneko, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT04285450: The Clinical Effect of Vitamin K Administration in Type 2 Diabetic Patients
Official title: The Clinical Effect of Vitamin K Administration in Type 2 Diabetic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-02-26
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to examine the possible clinical effects associated with vitamin K supplementation on the glycemic control, insulin sensitivity and lipid profile of type II diabetic patients.


Eligibility criteria: Inclusion Criteria:

* Adult patients 21-65 years old diagnosed with Type II diabetes.
* Fasting blood glucose concentration ≥ 126 mg/dL .
* Normal liver Function tests defined as ALT levels up to 33 U/L for males and up to 25 U/L for females, Albumin levels ≥ 3.5 g/dL, Bilirubin up to 1.1 mg/dL .
* Normal clotting function defined as defined by INR.
* Normal kidney function defined as serum creatinine values up to 1.3 mg/dL.

Exclusion Criteria:

* Type I diabetic patients.
* Use of supplements with potential effect on vitamin K level namely supplements containing vitamin K, co-enzyme Q10 or vitamin E \> 400 IU .
* Patients requiring anti-coagulant therapy including patients with prosthetic valves, mitral tissues, DVT, PE, atrial fibrillation and valvular heart disease.
* Patient with history of coagulation, MI, stroke and embolization.
* Pregnant or breast feeding women.
* Being on hormonal therapy or receiving contraceptive pills.
* Patients treated with glucocorticoids, thiazide diuretics, and atypical antipsychotics.
* Patients on cholestyramine, antibiotics and coumarins.
* Patients on lipid lowering agents.
* Known intestinal malabsorption syndrome, cholestasis or steatorrhea.
* Smokers.

Primary outcomes:
measure: Homeostasis model assessment of insulin resistance (HOMA-IR)
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr Al Aini Hospital
Study officials:
References:
Clinical trial NCT06751550: Changes in FeNO Value During Pulmonary Rehabilitation in Patients with Asthma
Official title: Change in Daily FeNO During Three Weeks of Inpatient Pulmonary Rehabilitation in Patients with Asthma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma Bronchiale
Asthmatic Patients
Asthmatics
Keywords: FeNO
Fractional Exhaled Nitric Oxide
Lead sponsor: Schön Klinik Berchtesgadener Land
Sponsor class: OTHER
Collaborators: name: Bosch Healthcare Solutions GmbH
First posted: 2024-12-30
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be recruitet at the pulmonary rehabilitation center at the Schön Klinik Berchtesgadener Land in Schönau am Königssee, Germany

Brief summary: This study investigates the use of fractional exhaled nitric oxide (FeNO) measurement to monitor non-pharmacological therapy during a three-week inpatient rehabilitation programme for asthma patients. It compares FeNO levels (measured three times a day) with clinical parameters and quality of life to analyse daily fluctuations and the acute effect of exercise training on FeNO levels. As FeNO is a non-invasive biomarker of airway inflammation, this study aims to expand its role in therapy monitoring and explore its application in a rehabilitation setting.


Eligibility criteria: Inclusion Criteria:

* confirmed diagnosis of bronchial asthma (all disease severities)
* Chronic Obstructive Pulmonary Disease (COPD) with an asthma component, where the asthma component plays a clinically relevant role
* written informed consent

Exclusion Criteria:

* Chronic Obstructive Pulmonary Disease (COPD) as the primary disease
* unability to perform FeNO measurement independently

Primary outcomes:
measure: Fractional Exhaled Nitric Oxide (FeNO) at rest
timeFrame: From enrollment to the end of rehabilitation at 3 weeks. Daily measurements at 9AM; 1PM; 5PM
measure: Fractional Exhaled Nitric Oxide (FeNO) before/after exercise
timeFrame: From enrollment to the end of rehabilitation at 3 weeks, FeNO measurements will be done before and after a bicycle endurance training
Secondary outcomes:
measure: Asthma control
timeFrame: On admission and discharge from the 3-week rehabilitation programme
measure: Lung function
timeFrame: On admission and discharge from the 3-week rehabilitation programme
measure: Eosinophils
timeFrame: On admission and discharge from the 3-week rehabilitation programme
measure: C-reactive protein
timeFrame: On admission and discharge from the 3-week rehabilitation programme
measure: Immunoglobulin E (IgE)
timeFrame: On admission and discharge from the 3-week rehabilitation programme
measure: 6-minute walk test
timeFrame: On admission and discharge from the 3-week rehabilitation programme
Other outcomes:
Locations:
city: Schonau am Konigssee
country: Germany
facility: Schön Klinik Berchtesgadener Land
Study officials:
References:
Clinical trial NCT01307150: Climatotherapy At The Dead Sea For Atopic Dermatitis
Official title: Evaluation of the Efficacy of Dead Sea Climatotherapy on Atopic Dermatitis Patients.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atopic Dermatitis
Keywords: Atopic Dermatitis
Dead Sea
Climatotherapy
SCORAD
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2011-03-02
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Atopic Dermatitis patient.

Brief summary: The purpose of this study is to evaluate the improvement in severity of Atopic Dermatitis and quality of life after 4 weeks of treatment in the Dead Sea.

Detailed description: 28 days treatment period, sun exposure and possibly Dead Sea baths after an exact given plan, discontinuation of all local Cortisone preparations, unlimited use of maintenance drags, doctor visit twice a week, continuous checks by the nurse.

Determination of the SCORAD index by the same doctor on arrival and departure. Before and after the treatment, the patient will answer written questionnaires regarding quality of life.

Eligibility criteria: Inclusion Criteria:

* Minimum age of 18 years old

Exclusion Criteria:

* Skin type - I
* Psoriasis patient in addition to Atopic Dermatitis
* Pregnancy
* Past malignancy
* Less then 2 weeks of treatment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: DMZ Clinic
Study officials:
affiliation: Hadassa Medical Organization IRB
name: Arie Ingber, MD.
role: STUDY_CHAIR
References:
citation: Harari M, Shani J, Seidl V, Hristakieva E. Climatotherapy of atopic dermatitis at the Dead Sea: demographic evaluation and cost-effectiveness. Int J Dermatol. 2000 Jan;39(1):59-69. doi: 10.1046/j.1365-4362.2000.00840.x.
Clinical trial NCT01451450: Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy
Official title: A Phase II, Randomized, Double Blind, Placebo-controlled, Parallel Design, Dose Ranging, Multi-center Trial of Four Levels of Exposure of QGE031 s.c. for 16 Weeks in Subjects Aged 18-50 Years of Age With Peanut Allergy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Peanut Allergy
Keywords: Peanut Allergy
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2011-10-13
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will assess the clinical potency of several exposure levels of QGE031 in decreasing the sensitivity against peanut allergen.


Eligibility criteria: Main Inclusion Criteria:

* Diagnosis of acute peanut allergy as manifested by urticaria, angioedema, gastro-intestinal or respiratory tract symptoms, with acute onset of symptoms after ingestion (up to 2 hours).
* Positive peanut food challenge at baseline, i.e., have objective allergic events at a level of 300mg (not cumulative) or below of peanut protein but not to the placebo test.

Main Exclusion Criteria:

* Prior exposure to any monoclonal antibody treatment
* Asthma patients on maintenance long acting beta-agonists
* Use of systemic corticosteroids
* Concomitant use of beta blockers, ACE inhibitors, tiotropium or ipratropium, antidepressants, oral beta-agonists
* Use of immunosuppressants within 6 months of visit 1 Other protocol-defined inclusion/exclusion criteria may appy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: